Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH–cortisol and renin–angiotensin–aldosteroneSequential chemotherapyFOLFIRIFOLFOXEndocrine axisACTH–cortisolRenin–angiotensin–aldosteroneThe chemotherapies of FOLFOX (leucovorin+5-fluorouracil+oxaliplatin) and FOLFIRI (folinic acid...
Friday, Kathleen will start the FOLFIRI, which is a second line chemo. Supposedly the side effects are not as bad as FOLFOX, but everyone reacts differently. As its a second line drug, it is normally not as effective as FOLFOX. But she wants to try and there is still a reasonable ...
临床肿瘤内科手册[M]北京:人民卫生出版 [11] LorizzoK,FazioN,RadieeD.SimplifiedFOLFIBIinpre—trea- 社,2007:149—153. tedpatientswihtmetastaticgastriccancer[J].CancerChemohter [3] 马冬,杨学宁.NCCN 胃癌临床指南 2009年[J].循环医学, Pharmacol,2008,l1:26. 2004,4(1)256. [12] CeliaL,Steniber...
Targeted therapy against VEGF and EGFR both demonstrated clinical activity in combination with chemo in MCRC. In 1st line, B with Folfox or Xelox increase ... C Tournigand,G Lledo,J Delord,... - 《Asco Meeting Abstracts》 被引量: 43发表: 2007年 A phase II, randomized study of aprepita...
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Abstract. Ann Oncol. 2021;32(suppl 5):S1329-S1330. doi:10.1016/j....
The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and che... PurposeThis study was designed to analyze the impacts of status of EGFR-associated genes on the outcome of chemo-refractory mCRC patients ...
Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II/sta
ChineseJournalofMedicinalGuide 2014Volume16No.3(SerialNo.125) 456 结肠癌一旦确诊,20%～30%已属晚期,丧失手术机会, 预期寿命仅为8个月,远处转移是结肠癌患者主要的死亡原 因,约30%结肠癌根治术后死于肿瘤复发 [1,2] 。常用的一线 治疗方案是FOLFOX方案和FOLFIRI方案 [3] 。2个方案在有 效率和生存期方面...
The toxicity was acceptable in both patients.ConclusionWe concluded that oxaliplatin-based combination chemotherapies (eg FOLFOX4) may achieve good tumor response without significant side effects in patients with metastatic colorectal cancer and hepatic dysfunction....
PledPharma launched the multicenter Phase lib PLIANT trial, intended to evaluate whether pretreatment with a stabilized form of mangafodipir, PledOx (calmangafodipir or PP-095), can reduce the severe side effects caused by the chemo agent FOLFOX in patients treated for metastatic colorectal cancer...